Financials

News Ideas Technicals

LIDDS fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

—

—

—

—

—

—

—

—

About

LIDDS AB develops pharmaceutical products for cancer and other diseases with NanoZolid technology. Its pipeline include NZ-Liproca Depot, NZ-DTX, NZ-DOX, NZ-IO, NZ-TLR9 and NZ-STING. The company was founded on November 4, 1999 and is headquartered in Uppsala, Sweden.

Valuation

Fundamental metrics to determine fair value of the stock

Summary

No data available

There's currently no market capitalization, revenue or net income data to show.

Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

LIDDS does not pay dividends

The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company